Article
In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019.
Diagnostic microbiology and infectious disease - 1 Sept 2021
Walkty Andrew, Karlowsky James A, Baxter Melanie R, Adam Heather J, Golden Alyssa, Lagace-Wiens Philippe, Zhanel George G
Abstract excerpt
Broth microdilution was used to determine the in vitro activities of imipenem-relebactam and comparators versus 4260 Enterobacterales and 1324 Pseudomonas aeruginosa clinical isolates. Excluding Serratia marcescens, 96.7% to 100% of Enterobacterales species were susceptible to imipenem-relebactam. Susceptibility of P. aeruginosa isolates to imipenem-relebactam and imipenem was 91.3% and 59.1%, respectively.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.